In LN229 cells, both PAD2 and PAD4 inhibitor also had some significant anti-oncogenic effect by reducing miR21 by 4.6 and 3.4-fold, respectively (Figure 4D), but did neither up-regulate miR126 (protective in GBM) nor have significant effects on miR210 in cell-derived EVs (Figure 4F). Here, PADI2 is linked to glioblastoma.